SPPH.US Spencer Pharmaceutical Inc
- Market cap
- -
- P/E
- -
- P/B
- 0.35x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2010.
Is SPPH.US undervalued?
Graham numberThe Graham number of Spencer Pharmaceutical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spencer Pharmaceutical Inc fundamental analysis
No fundamental analysis for Spencer Pharmaceutical Inc yet.
Spencer Pharmaceutical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spencer Pharmaceutical Inc
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America an…
Full company profileSpencer Pharmaceutical Inc financial statements
Spencer Pharmaceutical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2008 | 2009 | 2010 |
|---|---|---|---|
| Income Statement | |||
| Revenue | 441K | 0.00 | 0.00 |
| Gross Profit | 441K | 0.00 | 0.00 |
| Operating Income | 441K | -943K | -943K |
| Net Income | 441K | 0.00 | -943K |
| Balance Sheet | |||
| Total Assets | 0.00 | 57.6K | 772K |
| Total Liabilities | 0.00 | 57.6K | 1.64M |
| Shareholders' Equity | 0.00 | 0.00 | -871K |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||
| Operating Cash Flow | -898.00 | 57.6K | 642K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 |
| Ratios | |||
| ROA | - | 0.0% | -122.1% |
| Net Profit Margin | 100.0% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Spencer Pharmaceutical Inc dividends
Spencer Pharmaceutical Inc has not paid dividends in the last 3 fiscal years.
Last stock split: 1:25 on Oct 5, 2009.
Who owns Spencer Pharmaceutical Inc
Ownership data of Spencer Pharmaceutical Inc is not available yet.
Spencer Pharmaceutical Inc company profile
- Company name
- Spencer Pharmaceutical Inc
- Ticker
- SPPH.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 8 Faneuil Hall Marketplace, Boston, MA, United States, 02109
- Phone
- 617-973-5017
- Website
- -
About Spencer Pharmaceutical Inc
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Spencer Pharmaceutical Inc management
1- Dr. Maximilien Arella Ph.D.Chairman, Chief Executive Officer and President · born 1956